Network meta-analysis of finerenone and SGLT2 inhibitors in heart failure with preserved or mildly reduced ejection fraction
New analysis shows finerenone and SGLT2 drugs help lower heart failure hospitalization risks for patients with preserved ejection fraction
This network meta-analysis evaluated finerenone, sodium–glucose cotransporter 2 inhibitors, renin–angiotensin system inhibitors, and angiote…
A large review of over 65,000 patients found that finerenone and SGLT2 inhibitors reduce hospital stays and worsening heart failure compared…
Combining finerenone with SGLT2 inhibitors lowers mortality and cardiovascular events in diabetic chronic kidney disease patients
A Two-Drug Combo May Save Lives in Diabetic Kidney Disease
A meta-analysis of 1,580 patients shows dual therapy with finerenone and SGLT2 inhibitors significantly reduces mortality and kidney events …
A new analysis finds that pairing finerenone with an SGLT2 inhibitor may significantly lower the risk of death and heart problems for people…
Systematic review and meta-analysis of MRAs in dialysis patients shows reduced nonfatal CVD events but elevated hyperkalemia and gynecomastia risks
New analysis shows dialysis drugs cut heart attacks but raise dangerous potassium risks
This systematic review and meta-analysis evaluated mineralocorticoid receptor antagonists (MRAs) in adults on maintenance dialysis.
A large review of dialysis patients found that specific heart drugs reduced nonfatal heart events but increased risks of severe potassium bu…
Finerenone linked to improved KDIGO risk categories in T2D and CKD patients
Does finerenone help kidney risk categories improve in diabetes patients compared to placebo?
A post hoc subanalysis of an RCT in patients with type 2 diabetes and chronic kidney disease found finerenone therapy was associated with a …
Patients with diabetes and kidney disease taking finerenone were much more likely to see their kidney risk category improve and less likely …